CIBC Asset Management Inc Buys 8,490 Shares of IQVIA Holdings Inc. (NYSE:IQV)

CIBC Asset Management Inc boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 263,752 shares of the medical research company's stock after buying an additional 8,490 shares during the quarter. CIBC Asset Management Inc owned approximately 0.15% of IQVIA worth $62,501,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IQV. Empowered Funds LLC boosted its holdings in shares of IQVIA by 35.5% during the 1st quarter. Empowered Funds LLC now owns 2,512 shares of the medical research company's stock worth $635,000 after purchasing an additional 658 shares during the last quarter. Sei Investments Co. grew its holdings in shares of IQVIA by 4.8% during the 1st quarter. Sei Investments Co. now owns 57,887 shares of the medical research company's stock worth $14,638,000 after purchasing an additional 2,638 shares during the period. HBK Sorce Advisory LLC increased its position in shares of IQVIA by 10.9% during the 1st quarter. HBK Sorce Advisory LLC now owns 989 shares of the medical research company's stock worth $250,000 after purchasing an additional 97 shares during the last quarter. Great Lakes Retirement Inc. increased its holdings in IQVIA by 3.6% in the 1st quarter. Great Lakes Retirement Inc. now owns 2,393 shares of the medical research company's stock valued at $605,000 after purchasing an additional 84 shares during the last quarter. Finally, Banco Santander S.A. acquired a new stake in IQVIA during the 1st quarter worth approximately $419,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company's stock.

IQVIA Price Performance

NYSE IQV traded down $9.50 during midday trading on Friday, hitting $193.44. The company had a trading volume of 3,564,157 shares, compared to its average volume of 1,138,878. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $189.63 and a twelve month high of $261.73. The company has a market capitalization of $35.11 billion, a PE ratio of 25.62, a P/E/G ratio of 2.17 and a beta of 1.51. The firm has a 50-day moving average price of $227.96 and a 200-day moving average price of $228.59.

Wall Street Analyst Weigh In

Several equities analysts have commented on IQV shares. Evercore ISI dropped their price target on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. The Goldman Sachs Group lowered their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a report on Tuesday, November 5th. Morgan Stanley dropped their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Finally, Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They issued a "buy" rating and a $276.00 price target for the company. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $259.13.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.